Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 872 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Genetic Assessment Clear all
Not yet recruiting Not applicable Interventional

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

NCT07787156
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Interventions
Telephone education session, Online educational materials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational

Genetic Load and Phenotype in Aggressive AMD

NCT01650948
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
RetnaGene AMD LDT
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

NCT00621452
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Genetic + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational

Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders

NCT03967743
View directory record Official record
Conditions
Genetic Disease, Genetic Syndrome, Genetic Predisposition to Disease, Development, Infant, Development, Child
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 4 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Not listed Phase 1Phase 2 Interventional

Single Ascending Dose Study in Participants With LCA10

NCT03872479
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital
Interventions
EDIT-101
Drug
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Not listed Not applicable Interventional

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

NCT05846113
View directory record Official record
Conditions
Kidney Diseases
Interventions
Renasight
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

NCT05068024
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
FWD1509 MsOH
Drug
Lead sponsor
Forward Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Canton, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Factors in Age-Related Macular Degeneration

NCT00058695
View directory record Official record
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

NCT05877404
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Surveys
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Precision Nutrition Impact on Health-Related Behavior Change

NCT04959318
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Professional nutrition counseling, No professional nutrition counseling
Other
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 45 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

NCT00695422
View directory record Official record
Conditions
Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions
polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

NCT02777931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study

NCT01736345
View directory record Official record
Conditions
Candidates for BRCA 1/2 Genetic Testing
Interventions
Genetic Providers, Visual Aids, Post-Disclosure Asessments, In-person Clinical Follow-Up, 6 Month and 12 Month Assessments
Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
5
States / cities
Chicago, Illinois • Camden, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Not applicable Interventional

CBPR - BRCA Genetic Testing Among Orthodox Jews

NCT03624088
View directory record Official record
Conditions
Breast Cancer
Interventions
RealRisks
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
25 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

NCT05868486
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration
Procedure · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718910
View directory record Official record
Conditions
DDX3X, Mental Retardation, X-linked 102, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

NCT01476410
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

NCT05568420
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of Infants With Spinal Muscular Atrophy:

NCT02831296
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

NCT01339663
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes
Drug · Biological · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 5, 2026, 10:05 AM EDT